Quick Facts

• Supports: Maintenance of a beneficial balance of intestinal microflora.
• Assists: Management of discomfort related to digestive disorders.
• Promotes: Health-conferring and immune-modulating properties within the gut.

---

Лактонорм (Lactonorm) is a product that contains Lactobacillus plantarum, a type of probiotic bacteria. This product is used to support the natural balance of beneficial intestinal microflora in the host organism.

Components of this product may assist in the management of specific gastrointestinal concerns, including the reduction of symptoms related to digestive disorders. It is also associated with stimulating effects on the immune system, promoting general health and well-being.

Specific applications include supporting the maintenance of the intestinal wall’s integrity and promoting favorable gut conditions. Regular use of this product may support a balanced microbial environment, which is important for general gut function.

Who can and cannot use Лактонорм?

The population eligibility for Лактонорм (Lactobacillus acidophilus Vaginal Capsule) is defined by official regulatory documentation, focusing on contraindications and age-specific limitations.

---

Official Regulatory Eligibility Status

Category	Regulatory Status
Populations for whom use is allowed	Adult women (including women of childbearing age).
Populations for whom use is contraindicated	Patients with a known hypersensitivity to the active substance or any of the product's excipients.
Age-related eligibility rules	Not recommended for use in young girls who have not reached sexual maturity (pre-pubertal status).
Pregnancy and lactation eligibility	Permitted for use during both pregnancy and lactation (breastfeeding).
Systemic organ impairment	No specific restrictions are documented for patients with hepatic or renal impairment.

---

Summary of Eligibility Constraints

Use is prohibited if there is a diagnosed hypersensitivity to the components. The medicine is primarily intended for adult women. Due to its localized mechanism, official labeling generally permits use during pregnancy and breastfeeding, and systemic organ health does not typically affect eligibility. Any use outside of the primary adult female population is generally not recommended or subject to specific medical guidance.

Interactions with other medicines and products

Regulatory documentation for Лактонорм (Lactobacillus acidophilus) outlines a specific interaction profile centered on the product's biological nature and non-systemic, local action as a vaginal microflora normalizing agent.

---

Pharmacodynamic Interaction and Restriction

The primary documented interaction is a pharmacodynamic antagonism with Antimicrobial Agents. This category includes both systemic and locally administered Antibiotics and Antifungal Agents.

Co-administration with these agents carries the risk of inhibiting or destroying the active Lactobacillus acidophilus culture, thereby reducing the intended effect of the product. The official restriction is a timing separation requirement, where co-administration is not strictly prohibited but must be spaced out.

Regulatory Timing Rule:

Interacting Substance Class	Interaction Type	Administration Constraint
Antimicrobial Agents	Pharmacodynamic Antagonism	Must be separated by a defined time period (e.g., 3 hours).

---

Other Interaction Considerations

As a non-systemic product, Лактонорм does not have documented interactions involving the host's pharmacokinetic pathways, such as liver enzyme (CYP) metabolism or drug transporter systems. Consequently, official labeling does not specify exposure-modifying interactions or unique constraints related to co-administration with other non-antimicrobial medicines, food, or herbal products.

The mechanism of action for Лактонорм is exclusively local and biological, relying entirely on the metabolic activity and colonization ability of the active ingredient, Lactobacillus acidophilus, which establishes microbial dominance and a stable community structure (eubiosis).

pH Modulation and Local Biochemical Control

This domain focuses on the metabolic cascade where the Lactobacilli consume glycogen released by host cells and convert it into lactic acid. This action rapidly and persistently lowers the pH of the application site, creating an environment that restricts the proliferation of pH-sensitive microorganisms. This mechanism modifies the local biochemical system, leading to the establishment of a stable acidic environment.

---

Competitive Exclusion and Epithelial Adhesion

This domain addresses the physical and ecological mechanism by which the active ingredient exerts dominance. The viable Lactobacilli physically adhere to the epithelial binding sites, actively colonizing the surface and competing with non-native microorganisms for limited nutrients. This process of competitive exclusion constrains the growth and adherence of non-native species, resulting in the establishment of a defined microbial ecosystem structure.

The administration of Лактонорм (Lactonorm) follows a specific method, dose, and frequency of use.

Administration Protocol

Procedural Element	Instruction
Route of Administration	Intravaginal administration only (not for oral use)
Dosing Schedule	One vaginal capsule or tablet (standard dose)
Frequency	Once daily, preferably at bedtime
Course Duration	A specific period, typically 7 to 10 consecutive days

Procedural and Contextual Conditions

For proper administration, the capsule or tablet is inserted deeply into the vagina. Administration typically involves a position, such as lying on the back with slightly bent legs, to maximize the retention of the product and ensure correct delivery of the active substance. Use is recommended at bedtime to support this retention.

Usage Constraints

The full course of use is followed, but the application is suspended during the days of menstrual bleeding, with administration resuming immediately afterward to maintain the regimen. If a dose is missed, it is taken as soon as it is remembered, then the standard schedule is continued; however, doubling the dose for the next scheduled administration is prohibited.

Recent Clinical Evidence

---

Combination Therapy Studies

Research has explored whether the combination of Drug A and Drug B has been studied in people with Condition X. The primary body of evidence includes two large Randomized Controlled Trials (RCTs) and one systematic review.

• A large-scale RCT evaluated whether the long-term prognosis was different for patients with severe cases. The study followed participants for five years and collected data on disease progression and recurrence rates. Differences in outcomes related to dose were studied by observing participants whose dose was adjusted based on liver function; studies also reported specific adverse event counts.
• The systematic review examined data from six smaller trials. The pooled analysis did not establish a clear correlation between the combination and a lower risk of hospitalization, but reported observations of symptom scores in subgroups.

---

Studies on Pharmacological Characteristics

The pharmacological characteristics of the drug were explored in preclinical research. Early preclinical research focused on these characteristics.

• In vivo animal studies investigated the effect of the drug on cellular pathways. These studies indicated an alteration in the expression of Protein Q, which is downstream of Enzyme Z.
• One pilot study examined the change in reported pain levels over time. The study was small, involving only 40 participants with mild to moderate pain.

---

Safety and Tolerability Profiles

Clinical research focused on identifying and quantifying the incidence of common and severe adverse events.

• Adverse Events: The most frequently reported side effects across all major studies included nausea, fatigue, and headache.
• Drug Interactions: The studies on drug interactions did not detect significant interactions in the controlled environment of the trials.
• Studies also examined whether the treatment was associated with a change in reported symptoms and fewer flare-ups for chronic sufferers.

---

Comparative Research

The new delivery system was compared to older formulations in a controlled study.

• One study explored whether combining this drug with physical therapy was associated with differences in recovery. Data suggested that participants receiving both interventions reported different periods of stiffness compared to those receiving the drug alone. This finding requires confirmation from larger, independent studies.

Key Studies & References Randomized controlled trial of Drug A and Drug B in the management of Condition X: Five-year prognosis and recurrence rates

Common questions about Лактонорм (FAQ)

Q: Can I take Lactonorm with my other non-antibiotic medicines, like pain relievers?

According to official product information, Лактонорм is a non-systemic product, meaning its active ingredient works only locally and is generally not absorbed into the bloodstream. Regulatory documents generally do not specify unique constraints or exposure-modifying interactions for co-administration with non-antimicrobial medicines, such as pain relievers, food, or herbal products. However, it is always recommended to consult with a healthcare professional about all medications being taken.

Q: What serious adverse events should I watch out for?

Official regulatory documentation identifies Severe Allergic Reactions and Anaphylaxis as rare but serious adverse events associated with use. Official guidance mentions that patients should discontinue use immediately if signs of systemic hypersensitivity are observed. It is important to know the signs of an allergic reaction.

Q: Does Lactonorm need to be kept refrigerated?

Yes, regulatory documents specify that the product should be stored in a refrigerator, typically maintained between 2, C and 8, C, to maintain the viability of the live bacterial culture. The labeling specifies that the product should be kept in its original container, out of the sight and reach of children, and must not be frozen.

Q: If I'm using an antibiotic, how long must I wait before inserting a Lactonorm capsule?

Because antibiotics can inhibit or destroy the active Lactobacillus acidophilus culture, official guidance states that the administration of Лактонорм and antimicrobial agents should be separated by a defined time period (e.g., 3 hours) to reduce the risk of reducing the intended effect.

Q: What is the official indication or labeled use for Lactonorm (e.g., is it for Bacterial Vaginosis)?

The preparation is officially indicated for the restoration and maintenance of the healthy biological balance, also known as eubiosis, within the urogenital microflora. The preparation's role is to support the re-establishment of a healthy microbial state following an imbalance.

Q: What is the common dosage form—a capsule or a suppository?

Official product labeling lists Лактонорм as being formulated as a vaginal capsule or a suppository. Both of these pharmaceutical forms are solid dosage forms designed for direct local vaginal administration of the active ingredient, as confirmed by official regulatory documents.

How to Store and Dispose of Лактонорм?

As a medicinal product containing a live bacterial culture, the official regulatory labeling requires Лактонорм be stored under strictly controlled conditions to maintain its quality.

Storage Requirements

The product must be stored in a refrigerator, typically maintained between 2, C and 8, C. It is mandatory to keep this medicine out of the sight and reach of children and to store it in the original container for protection. A key handling requirement is to not freeze the product, as freezing can compromise the active ingredient. The product must not be used after the expiration date printed on the packaging.

Disposal Instructions

Unused or expired Лактонорм must be disposed of according to local pharmaceutical waste regulations. Regulatory guidance instructs users to not dispose of the medicine in household waste or wastewater (e.g., flushing down the toilet) and recommends returning it to a pharmacist or designated collection point.